Light Line Medical, Inc.’s patented visible-light platform technology is an infection prevention game-changer, destined to create a massive global shift in how the world prevents and treats heath care associated infections. The CDC reported that each year over 2 million people in the United States are infected by antibiotic resistant bacteria and over 23,000 people die from these infections . Without relying on drugs, chemicals, or UV light, visible light technology is the first antimicrobial for all infections, including antibiotic resistant bacteria, which the CDC has identified as “one of the world’s most pressing public health threats” . Light Line Medical has developed a proprietary method of delivering light to prevent and treat catheter associated infections. This technology uses non-UV visible light to kill bacteria and prevent biofilm both intra and extraluminally. Light Line Medical has four revolutionary systems in development that are compatible with off-the-shelf catheters and endotracheal tubes (we are not manufacturing catheters). Our first four products have the potential to dramatically decrease the frequency of peritoneal dialysis and hemodialysis infections, urinary tract infections, bloodstream infections, and ventilator associated pneumonia. Results show a dramatic reduction in bacteria between control and light treated groups. SEM images from in vitro testing of Light Line's prototype Foley catheter show the extraluminal contrast in bacteria growth between test and control groups.